Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $20.5 million.

  • Day One Biopharmaceuticals' Non-Current Assets rose 20.18% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 20.18%. This contributed to the annual value of $20.5 million for FY2024, which is 2543.15% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Non-Current Assets stood at $20.5 million, which was up 2,543.15% from $774,000 recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Non-Current Assets registered a high of $20.5 million during FY2024, and its lowest value of $774,000 during FY2023.
  • Moreover, its 3-year median value for Non-Current Assets was $1.2 million (2022), whereas its average is $7.5 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Non-Current Assets tumbled by 34.85% in 2023 and then soared by 2,543.15% in 2024.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Non-Current Assets stood at $1.2 million in 2022, then crashed by 34.85% to $774,000 in 2023, then soared by 2,543.15% to $20.5 million in 2024.